X4T-12910-28389
3 vaccinations
2 coded responses
29 check-ins
2 free-text entries
1 call case
- Sex
- Female
- Age at first dose
- 46-50
- ZIP prefix
- 606 / IL
- Registered
- 2021-01-06
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-01-06
Registered in v-safe
-
2021-01-06
Dose 1 — Pfizer-BioNTech
- 2021-01-06
- 2021-01-07
- 2021-01-08
-
2021-01-09
Health check-in — days 1–6 daily, dose 1Feeling: Good · Site: Pain · Fatigue or tirednessAdult check-in
- 2021-01-10
- 2021-01-11
- 2021-01-12
- 2021-01-15
- 2021-01-21
-
2021-01-27
Dose 2 — Pfizer-BioNTech
- 2021-01-27
-
2021-01-28
Survey response — days 1–6 daily, dose 2MedDRA: Hyperhidrosis — Feeling: Fair · Site: Pain · Fever · Chills, Joint pains, Muscle or body aches, Fatigue or tiredness, Nausea · Be unable to do your normal daily activitiesFree text: SweatingMedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
-
2021-01-29
Health check-in — days 1–6 daily, dose 2Feeling: Fair · Site: Pain · Fatigue or tirednessAdult check-in
- 2021-01-30
- 2021-01-31
- 2021-02-01
- 2021-02-03
- 2021-02-10
- 2021-02-17
- 2021-02-26
- 2021-03-03
- 2021-03-12
- 2021-07-30
-
2021-09-03
Dose 3 — Pfizer-BioNTech
- 2021-09-29
- 2021-10-03
- 2021-10-10
- 2021-10-16
- 2021-12-05
- 2022-03-04
-
2022-09-05
Survey response — 12 months, dose 3MedDRA: COVID-19, Cough, Pelvic organ prolapse — Feeling: Fair · Be unable to work or attend school, Be unable to do your normal daily activities, Get care from a doctor or other healthcare professional · Telehealth, virtual health, or email health consultationFree text: Covid in January 2022. Horrible 3-month cough that contributed to new pelvic prolapse, so symptoms related to pelvic prolapse.MedDRA releases: 2024-11 · check-in free text available
-
2022-09-05
Report sent to call center — 12 months, dose 3Be unable to work or attend school · Be unable to do your normal daily activities · Get care from a doctor or other healthcare prTelehealth, virtual health, or email health consultation · 1 call case(s)
- 2022-09-07
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-01-06 | Pfizer-BioNTech | |
| 2 | 2021-01-27 | Pfizer-BioNTech | |
| 3 | 2021-09-03 | Pfizer-BioNTech | No |
Call center
| Reported | Outcome | VAERS-related outcome |
|---|---|---|
| 2022-09-05 | Unsuccessful |
Free text
Release 2 — days 1–6 daily, dose 2
Systemic reaction (other): Sweating
Release 12 — 12 months, dose 3
Symptoms: Covid in January 2022. Horrible 3-month cough that contributed to new pelvic prolapse, so symptoms related to pelvic prolapse.
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Cough | · | · | ✓ |
| SD | COVID-19 | · | · | ✓ |
| SD | Pelvic organ prolapse | · | · | ✓ |
| SRO | Hyperhidrosis | ✓ | ✓ | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release